Skip to content
2000
Volume 9, Issue 1
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/138945008783431754
2008-01-01
2025-09-03
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/138945008783431754
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test